Enhancement of Innate Immunity against *Mycobacterium avium* Infection by Immunostimulatory DNA Is Mediated by Indoleamine 2,3-Dioxygenase

TOMOKO HAYASHI,1 SAVITA P. RAO,1 KENJI TAKABAYASHI,1 JOHN H. VAN UDEN,1 RICHARD S. KORNBLUTH,1 STEPHEN M. BAIRD,2 MILTON W. TAYLOR,3 DENNIS A. CARSON,1 ANTONINO CATANZARO,1 AND EYAL RAZ1 *

Department of Medicine1 and Department of Pathology,2 University of California, San Diego, La Jolla, California 92093, and Department of Biology, Indiana University, Bloomington, Indiana 47405

Received 26 March 2001/Returned for modification 22 May 2001/Accepted 9 July 2001

Mycobacterium avium infection is a common opportunistic infection in patients with AIDS (22), while *M. avium* rarely causes disease in immunocompetent individuals. In AIDS, disseminated *M. avium* infection occurs only after severe depletion of CD4+ T cells (10) and is a major cause of morbidity and mortality. Although intensive antiretroviral therapy prevents the onset of *M. avium* infection to some extent (3), *M. avium* infection in AIDS is extremely difficult to treat when encountered because it responds poorly to available antimycobacterial therapies (33).

*M. avium* predominantly infects and multiplies within macrophages (14). This organism is known to attach to and enter macrophages with the help of complement, transferrin, and integrin receptors expressed on the surface of macrophages (6, 42). Macrophages secrete several cytokines in response to infection with this organism, including tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β), IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) (17, 38).

Immunostimulatory DNA sequences (ISS) were initially discovered in the mycobacterial genome as short DNA sequences that selectively enhanced NK cell activity (53). In addition, bacterial DNA or oligodeoxynucleotides containing ISS (ISS-ODN) activate antigen-presenting cells, such as dendritic cells and macrophages. ISS-ODN activation leads to the up-regulation of costimulatory receptors (32), the release of IFN-α/β, TNF-α, IL-12, and IL-18 (25, 28, 44, 47, 55), and the priming of Th1 responses and cytotoxic T-lymphocyte (CTL) responses to exogenous antigens (9, 30). This immune profile has been used to generate cellulary mediated immunity to conjoined antigens in the development of novel vaccine strategies (9, 29, 44).

Recent studies have also demonstrated the ability of ISS-ODN to facilitate control of the intracellular pathogens *Listeria monocytogenes*, *Leishmania major*, and *Franciscella tularensis* (24, 27, 51). This effect is generally attributed to the activation of innate immunity, which is crucial for both the initial control of *L. monocytogenes* and *L. major* and the long-term control from subsequent induction of Th1 and CTL responses.

Here, we examine whether ISS-ODN can modify the course of *M. avium* infection. Our studies demonstrate that ISS-ODN is able to restrict the growth of *M. avium* via the induction of indoleamine 2,3-dioxygenase (IDO), revealing a novel facet of ISS-ODN-induced activation of innate immunity. As a therapeutic adjunct, ISS-ODN significantly enhances the ability of the conventional antimycobacterial agent clarithromycin (CLA) to treat *M. avium* infection in mouse and human macrophages as well as in a mouse model of *M. avium* infection.

MATERIALS AND METHODS

**Mice.** Female C57BL/6 mice (7 to 8 weeks old) and 129/SvEv mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) and Taconic Laboratories, Germantown, New York, respectively. The inducible nitric oxide synthetase (iNOS−/−) IL-12 p40−/−, TNF-α−/−, and NADPH oxidase (gp91 phox−/−) knockout mice are on the C57BL/6 background and were purchased from The Jackson Laboratory. IFN-α/β receptor (IFN-α/βR−/−) and IFN-γ receptor (IFN-γR−/−) (129/EvSv background) knockout mice were obtained from B & K Universal, Ltd. (East Yorkshire, United Kingdom).

**Reagents and cytokines.** Endotoxin-free (<1 ng of DNA per mg) phosphorothioate single-stranded oligodeoxynucleotides were obtained from Trilink Bio-
technologies, San Diego, Calif. The sequence of the ISS-ODN was 5'-TGACT GTTGGTTFATTAGATGA-3'. The sequence of the mutated-ODN (M-ODN) was 5'-TGACTGTTGAAGGTATTAGATGA-3' (underlining indicates immunostimulatory sequences [ISS]). We used 10 μg of ISS-ODN or M-ODN per ml unless otherwise noted. t-Tryptophan (t-Try) was obtained from Gibco BRL (Grand Island, N.Y.) and Dulbecco’s modified Eagle’s medium (DMEM) was supplemented with t-Try for a final concentration of 66 μg/ml. 1-Methyl-tt-tryptophan (M-Try) was purchased from Aldrich Chemicals (Milwaukee, Wis.). Anti-CD3, anti-CD28, anti-CD4, and anti-CD8 monoclonal antibodies as well as monensin and mero recombinant IFN-γ were purchased from BD Pharmingen (San Diego, Calif.). Abbott Laboratories (Abbott Park, Ill.) kindly provided CLA.

Culture of M. avium and CFU assay. M. avium strain 113 isolated from an AIDS patient at University of California, San Diego (34), was used in all experiments. Bacteria were cultured as described previously (21). The numbers of CFU in a sample were determined by colony counting as described previously (39).

Preparation of murine macrophages and isolation of human monocytes. Murine bone marrow-derived macrophages (mBMDMs) were prepared from mouse bone marrow using L-cell conditioned medium, as described previously (32). Human monocytes were isolated from normal human buffy coats obtained from the San Diego Blood Center by Ficoll-Hypaque and Percoll gradient centrifugation (21) and then cultured in Teflon beakers for 7 days to yield mature human monocyte-derived macrophages (hMDMs). M. avium infection of macrophages in vitro. To study the protective effect of ISS-ODN treatment before infection, 5 × 10^6 mBMDMs or hMDMs were treated with ISS-ODN for 3 days before infection. Macrophages treated with M-ODN or with medium alone served as controls. After 3 days, the cells were infected with 2 h of M. avium at a macrophage/bacterium ratio of 2:1 for mBMDMs or 1:10 for hMDMs and subsequently cultured in fresh medium without antibiotics. To examine attachment and/or invasion of M. avium, the macrophages were lysed immediately after washing, and the number of bacteria was enumerated by the CFU assay. Intracellular growth of M. avium was determined on days 1, 3, and 7 after infection. To account for all of the mycobacteria in each well, corresponding lysates were combined with the culture media, and then the number of CFU was determined. To examine the efficacy of anticytotoxic treatments, CFU from cells treated with medium alone was considered as 100% growth.

To determine whether treatment with ISS-ODN after infection alters M. avium growth, adherent cells were first infected with M. avium for 2 h and then cultured with fresh medium containing ISS-ODN. Infected cells treated with M-ODN or medium alone served as controls. At day 7, intracellular growth of M. avium was assessed by the CFU assay. M. avium infection of mice in vivo. To study the effect of treatment with ISS-ODN before infection, mice were injected intradurally (i.d.) with ISS-ODN (50 or 100 μg/mouse) 3 days before infection, while control mice received phosphate-buffered saline (PBS). In the preliminary experiments, the numbers of CFU in the spleen and lungs were similar in the M-ODN-treated mice and control (PBS) treated mice 4 weeks after infection, but were significantly higher than those in the ISS-ODN-treated mice (by 2 logs in spleen and 1 log in lungs, respectively). Therefore, treatment with M-ODN was excluded in this set of experiments. All mice were infected intravenously (i.v.) with M. avium (10^7/mouse). At 2, 4, and 6 weeks after infection, the mice were sacrificed, and the spleen, liver, and lungs from each mouse were collected and weighed. A section of each organ was homogenized with 0.25% sodium dodecyl sulfate (SDS) in PBS. The number of CFU in the tissue homogenates was determined by the CFU assay, and the results were expressed as CFU per organ.

To study the effect of ISS-ODN when combined with CLA in vivo, 25 mice were infected with M. avium (10^7/mouse). One week after infection, treatment with either ISS-ODN or M-ODN and CLA was initiated. Mice were divided into five treatment groups (n = 5 per group): group 1, no treatment; group 2, ISS-ODN alone; group 3, CLA alone; group 4, CLA and ISS-ODN; and group 5, CLA and M-ODN. CLA (200 mg/kg of body weight) was administered intraperitoneally three times a week for 4 weeks as described previously (13), and bacterial growth in the spleen, liver, and lungs was determined.

Detection of intracellular IFN-γ by FACS and IFN-γ secretion by ELISA. Mice were injected i.d. with ISS-ODN (50 μg/mouse). The control mice received M-ODN (50 μg/mouse) or PBS. All mice were infected with 10^7 M. avium cells. Three days after infection, the mice were sacrificed, and spleenocytes from mice receiving the same treatment were pooled. Intracellular cytokine staining was performed with the Cytofix/Cytoperm kit (BD Pharmingen) according to the manufacturer’s instructions. Briefly, the splenocytes were stimulated with anti-CD3 and anti-CD28 activating antibodies in the presence of monensin to allow intracellular IFN-γ to accumulate for 6 h. Next, the cells were stained for surface CD3 and CD8 and fixed, and the plasma membranes were permeabilized, allowing for intracellular staining with anti-IFN-γ. The cells were analyzed by fluorescence-activated cell sorting (FACS) with a FACSCalibur flow cytometer (Becton Dickinson). To study IFN-γ secretion, splenocytes were incubated with anti-CD3 and anti-CD-28 antibodies or M. avium sonicates (20) at antigens in vitro for 24 h, and then the supernatant was assayed for IFN-γ secretion by enzyme-linked immunosorbent assay (ELISA) as previously described (32).

RNA extraction, RT-PCR, and IDO activity assay. mBMDMs (2 × 10^6) were treated with ISS-ODN or M-ODN. After 3 days, the cells were infected with M. avium for 2 h. At 24, and 48 h after infection, the M. avium-infected macrophages were lysed, and total RNA was isolated by using the Trizol reagent (Gibco BRL). The induction of IDO gene transcription was measured by semi-quantitative reverse transcription-PCR (RT-PCR). First-strand cDNA preparation and PCR amplification were carried out with the SuperScript Pre-amplification System (Gibco BRL) and AdvanTaq Plus DNA polymerase (Clontech, San Francisco, Calif., respectively). PCR products were visualized by electrophoresis on 2% agarose gels. The primer sequences used were as follows: IDO, 5’-TTATTCGACATGTGTCTTGCGAAA-3’ and 5’-TCTTCCAGCCAGACAGATATAAGCG-3’; and glucose-3-phosphate dehydrogenase (G3PDH), 5’-ACAGTTCCATGCCATCAC-3’ and 5’-TCCACCACTTCGTGCTGTA-3’.

Histological examination. Tissue sections of the spleen collected from the experimental and control mice were fixed overnight in 10% buffered formalin at room temperature and then embedded in paraffin. The paraffin-embedded tissue was further sectioned (5-μm thickness) and stained with hematoxylin-eosin. The sections were observed under an Olympus microscope. At least three sections of each organ from each of the experimental and control mice were evaluated.

Statistical analysis. Results are expressed as mean ± standard deviation (SD), and statistical differences were determined with the nonpaired Student’s t test (two-tailed distribution). A P value below 0.05 is considered to be statistically significant.

RESULTS

Treatment with ISS-ODN inhibits the growth of M. avium in vitro. M. avium is able to infect and replicate in macrophages (14). We performed the following studies to address whether ISS-ODN-induced activation of macrophages in vitro inhibits intracellular growth of M. avium.

(i) Treatment prior to infection. To examine whether treatment with ISS-ODN can stimulate macrophages to inhibit the growth of M. avium, mBMDMs were first treated with ISS-ODN or M-ODN (3, 10, and 30 μg/ml) for 2 h and then infected with M. avium. The number of CFU was counted on days 1, 3, and 7 postinfection (Fig. 1A). By day 7, treatment with ISS-ODN inhibited intracellular growth of M. avium in mBMDMs by 80% (P < 0.001). No significant difference in M. avium growth was seen among the different concentrations of ISS-ODN tested. Since viability of macrophages can affect M. avium growth, we assessed the viability of macrophages by trypan blue exclusion. At day 7 after infection, mBMDMs treated with ISS-ODN, M-ODN, or medium alone were all >90% viable. The experiments were terminated at day 7 after infection, since the viability of mBMDMs began to decline from this point on.

ISS-ODN activates macrophages and induces the expression of surface adhesion molecules such as ICAM-1 (32). These molecules may affect the attachment of M. avium or its invasion into mBMDMs. In order to determine whether the ability of ISS-ODN to inhibit M. avium growth is due to alterations in M. avium invasion, the ability of ISS-ODN to influence the number of bacteria that attached to and invaded mBMDMs after incubation with M. avium was examined. The number of CFU recovered immediately from cells treated with ISS-ODN before infection was not significantly different from the num-
(ii) Treatment after infection. To evaluate the therapeutic antimycobacterial effect of ISS-ODN, infected mBMDMs were treated with ISS-ODN for 7 days after infection, starting 2 h after the time of infection. Treatment with a single dose of ISS-ODN significantly decreased the intracellular growth of *M. avium* in mBMDMs by 68% (*P* < 0.05), compared to the number of CFU in infected cells treated with medium alone (Fig. 1B).

**ISS-ODN transiently inhibits the growth of *M. avium* in vivo.** To determine whether ISS-ODN can enhance resistance to *M. avium* infection in vivo, mice were treated with ISS-ODN and infected i.v. 3 days later with 10⁷ organisms per mouse. In a preliminary experiment, bacterial growth in spleen and lung from mice treated with 50 μg of ISS-ODN was similar to bacterial growth in mice treated with 100 μg of ISS-ODN 4 weeks after infection (data not shown). Therefore, we used 50 μg of ISS-ODN per mouse for the in vivo experiment. At 2, 4, and 6 weeks after infection, the number of CFU was determined in the spleen, lungs, and liver. Based on the preliminary experiments, which demonstrated no differences in colony counts among the ISS-ODN, M-ODN, or control mice at 6 versus 8 weeks postinfection, all future experiments were terminated at 6 weeks postinfection.

At week 2, the lungs of *M. avium*-infected mice treated with ISS-ODN prior to infection contained a significantly lower number of viable bacteria compared to control PBS-treated mice (*P* < 0.05) (Fig. 2A). In addition, mice treated with ISS-ODN prior to *M. avium* infection had nearly 2 logs fewer bacteria in the spleen at 4 weeks (*P* < 0.05) compared to the PBS-treated mice (Fig. 2B). By 6 weeks, however, the numbers of splenic CFU were similar in control and ISS-ODN groups. There was no significant difference in the mycobacterial loads in the liver of mice treated with ISS-ODN prior to infection compared to those of PBS-treated mice at any of these time points (Fig. 2C). Thus, a single injection of ISS-ODN significantly reduced the mycobacterial growth in the spleen and lungs, but not in the liver of *M. avium*-infected mice. This protective effect was transient and was most apparent at 2 and 4 weeks after a single administration of ISS-ODN.

Although treatment with ISS-ODN after infection inhibited *M. avium* growth in vitro, there was no difference in the mycobacterial counts in spleen and liver at any time point observed when we used ISS-ODN 1 week after infection in vivo. Overall, ISS-ODN significantly reduces the growth of *M. avium* when ISS-ODN was used in a preventive mode, but not when used in a therapeutic mode.

**ISS-ODN protection in vivo is not mediated through augmentation of the T-cell response.** The observation that ISS-ODN protects isolated macrophages in vitro (Fig. 1) and that the protective effect observed in ISS-ODN-treated mice is transient (Fig. 2) suggests a T-cell-independent mechanism of protection via innate immunity. To further investigate the potential role of adaptive immunity in this model of ISS-ODN-mediated protection against *M. avium*, mice were treated with ISS-ODN or M-ODN (50 μg/mouse) and infected with 10⁷ organisms/mouse, and then their T-cell response was evaluated. The mice were sacrificed at 3 weeks postinfection, and the splenocytes were restimulated with anti-CD3 and anti-CD28 antibodies or *M. avium* sonicates to amplify the response from preexisting memory and activated T cells. T cells were then examined for their production of IFN-γ, FACS-based intracellular cytokine staining was used to determine the frequencies of IFN-γ-producing CD4⁺ and CD8⁺ T cells (Fig. 3A, B, and C) and CD8⁺ T cells (Fig. 3B) T cells, while the total quantity of IFN-γ secreted by splenocytes was determined by ELISA (data not shown). There was a dramatic increase in the IFN-γ response of the CD4⁺ T cells in the infected versus uninfected animals, demonstrating that the observed Th1 response is infection specific. However, treatment of *M. avium*-infected mice with ISS-ODN did not further increase the frequency of IFN-γ-positive CD4⁺ or CD8⁺ T cells. In addition, treatment with ISS-ODN did not enhance the IFN-γ secretion by splenocytes, which were restimulated by anti-CD3 and anti-CD28 antibodies or *M. avium* sonicates, compared to M-ODN treatment (data not shown). These data, combined with the observation that ISS-ODN protects isolated macrophages in vitro (Fig. 1) and that the protective effect observed in ISS-ODN-treated
mice is transient (Fig. 2), suggest that it is unlikely T-cell-dependent immunity plays a role in the antimycobacterial effect of ISS-ODN during early stages of infection.

ISS-ODN inhibition of *M. avium* growth in macrophages is independent of iNOS, NAPDH oxidase, IL-12, TNF-α, IFN-α/β, and IFN-γ. To further investigate the mechanisms of the antimycobacterial effects of ISS-ODN, mice with targeted disruptions of genes known to play roles in *M. avium* infection were used. Oxygen radicals generated by NADPH oxidase and induction of nitric oxide (NO) by iNOS result in antimicrobial activity against many microorganisms (16, 35). IL-12, TNF-α, and IFN-γ play important roles in the clearance of *M. avium* (2, 13, 26). Furthermore, macrophages produce IL-12, TNF-α, and IFN-α/β in response to ISS-ODN treatment (25, 44). To study the role of these molecules in the antimycobacterial effect of ISS-ODN, mBMDMs from NADPH oxidase−/−, iNOS−/−, TNF-α−/−, IL-12 p40−/−, IFN-α/βR−/−, and IFN-γR−/− mice were treated with ISS-ODN for 3 days and then infected with *M. avium*. ISS-ODN inhibited the intracellular growth of *M. avium* in mBMDMs from these knockout mice by 60 to 85% (*P* < 0.05), similar to wild-type mice (Table 1). These results indicate that these gene products (e.g., nitrogen intermediates, oxygen radicals, TNF-α, etc.) are not central to the antimycobacterial effect induced by ISS-ODN in vitro.

**Induction of IDO contributes to the antimycobacterial activity of ISS-ODN.** Macrophages orchestrate the activation of innate immunity to directly attack an invading pathogen by secreting a battery of cytokines, expressing costimulatory molecules, and generating free radicals. However, macrophages also employ effector mechanisms to deny the pathogens required substrates for their growth. One such example is the depletion of tryptophan due to the induction of IDO. IDO is
the rate-limiting enzyme in the catabolism of tryptophan. Induction of this enzyme limits the availability of this important amino acid to invading pathogens (11). To study the potential role of IDO in the antimycobacterial effect of ISS-ODN, we assessed (i) the induction of IDO activity as measured by semiquantitative RT-PCR in vivo and in vitro and (ii) the abrogation of the antimycobacterial effect of ISS-ODN by addition of excess L-Try or by using a competitive inhibitor for IDO, M-Try.

When mice were injected i.v. with 50 μg of ISS-ODN, IDO gene induction was observed in the lungs and spleen after 16 h, but not in the liver (Fig. 4A). Injection of M-ODN did not result in any detectable induction of IDO (data not shown). For in vitro studies, mBMDMs were treated with ISS-ODN for 3 days prior to M. avium infection. Cells were then lysed at 4, 8, and 24 h after infection, total RNA was extracted, and semiquantitative RT-PCR was performed. We found that optimal induction of IDO gene transcription required both treatments with ISS-ODN and M. avium infection (Fig. 4B).

In order to further investigate the role of IDO in the inhibition of M. avium growth, mBMDMs were cultured with the IDO inhibitor M-Try (125 μM) or with excess L-Try (final concentration, 66 μg/ml) as previously described (23, 36). Addition of L-Try or M-Try alone at these concentrations did not alter the viability of mBMDMs or M. avium growth in mBMDMs (data not shown). However, when the M. avium-infected cells were cultured with L-Try or M-Try-supplemented medium, fourfold reductions in the antimycobacterial ability of ISS-ODN treatment were observed (P < 0.05) (Fig. 4C). Taken together, these data suggest that IDO plays a role in the observed antimycobacterial properties of ISS-ODN.

ISS-ODN is an adjunct to antimycobacterial therapy with CLA. Treatment of M. avium infection by conventional chemotherapy is difficult and requires prolonged administration (8, 33). In vivo experiments, ISS-ODN did not affect the colony counts when administered in an established infection.

FIG. 4. IDO is involved in the antimycobacterial effect of ISS-ODN. (A) ISS-ODN induced IDO gene expression in the lungs and spleen, but not liver. Uninfected mice were injected with 50 μg of ISS-ODN, and the lungs and spleen were collected 16 h after injection. Total RNA was isolated, and semiquantitative RT-PCR was performed to assess the induction of IDO gene expression. –, injected with saline; +, injected with ISS-ODN. (B) M. avium infection with ISS-ODN treatment of mBMDMs induces IDO gene expression. mBMDMs were treated with ISS-ODN for 3 days prior to infection with M. avium. Total RNA was evaluated by semiquantitative RT-PCR to assess the induction of IDO gene expression at 4, 8, and 24 h postinfection. Lanes: 1, medium alone; 2, ISS-ODN treatment alone; 3, M. avium infection alone; 4, ISS-ODN treatment and M. avium infection. (C) Addition of excess L-Try or a competitive IDO inhibitor, M-Try, partially inhibited the antimycobacterial effect of ISS-ODN. mBMDMs were treated with ISS-ODN for 3 days in the presence of excess L-Try (final concentration of 66 μg/ml) or M-Try (125 μM) and subsequently infected with M. avium for 7 days in the presence of L-Try or M-Try. Intracellular growth of M. avium was assessed by the CFU assay. Each condition was tested in triplicate, and the results are expressed as mean ± SD CFU per well. The results shown are representative of three experiments. *, P < 0.01 compared to CFU recovered from cells treated with ISS-ODN.

### TABLE 1. Effect of ISS on M. avium growth in mBMDMs from mice with targeted disruption of genes known to play a protective role against M. avium infection

<table>
<thead>
<tr>
<th>Mouse Strain</th>
<th>Untreated (10^6 CFU)</th>
<th>M-ODN</th>
<th>ISS-ODN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td>C57BL/6</td>
<td>100 (8.3)</td>
<td>117.2 ± 18.5</td>
</tr>
<tr>
<td>Wild type</td>
<td>129S6/SvEv</td>
<td>100 (15.0)</td>
<td>110.0 ± 15.9</td>
</tr>
<tr>
<td>NOS-/-</td>
<td>C57BL/6</td>
<td>100 (25.0)</td>
<td>105.0 ± 13.0</td>
</tr>
<tr>
<td>NADPH oxidase-/- (gp91 phox-/-)</td>
<td>C57BL/6</td>
<td>100 (14.3)</td>
<td>107.0 ± 15.5</td>
</tr>
<tr>
<td>TNF-α-/-</td>
<td>C57BL/6</td>
<td>100 (33.3)</td>
<td>120.0 ± 20.0</td>
</tr>
<tr>
<td>IL-12 p40-/-</td>
<td>C57BL/6</td>
<td>100 (22.7)</td>
<td>117.6 ± 9.2</td>
</tr>
<tr>
<td>IFN-αR-/-</td>
<td>129S6/SvEv</td>
<td>100 (14.5)</td>
<td>106.9 ± 11.9</td>
</tr>
<tr>
<td>IFN-γR-/-</td>
<td>129S6/SvEv</td>
<td>100 (9.2)</td>
<td>108.1 ± 10.8</td>
</tr>
</tbody>
</table>

* mBMDMs were treated with M-ODN or ISS-ODN (10 μg/ml) for 72 h prior to infection and then infected with M. avium mBMDMs treated with medium alone served as the control. On day 7, M. avium growth was assessed by CFU assay. The average numbers of CFU recovered in the wells of untreated BMDMs are indicated in parentheses. For comparison, results are presented as percent CFU compared to mBMDMs treated with medium alone, rather than absolute CFU, in order to normalize for strain variation (i.e., C57BL/6 versus 129S6/SvEv). The number of CFU of cells treated with medium alone was considered 100%. Mean ± SD from three independent experiments are shown.

* P < 0.05 compared to mBMDMs treated with medium alone.
Therefore, we hypothesized that coadministration of ISS-ODN along with a chemotherapeutic agent such as CLA may further enhance mycobacterial clearance.

mBMDMs were first infected with *M. avium* and then treated with CLA (0.1 μg/ml) in the presence or absence of ISS-ODN (10 μg/ml) or M-ODN (10 μg/ml), and *M. avium* growth in vitro was determined 7 days after infection. ISS-ODN and CLA (0.1 μg/ml), when used individually, reduced bacterial growth in mBMDMs by 68 and 84%, respectively (*P* < 0.01; Fig. 5A). When ISS-ODN was used together with CLA, bacterial counts were further reduced (95%, *P* < 0.01) compared to medium alone (Fig. 5A).

C57BL/6 mice were infected intravenously with *M. avium* (10⁶ CFU) and treated with a combination of ISS-ODN (50 μg/ml) and/or CLA (200 mg/kg of body weight) 1 week after infection. Mice were sacrificed 5 weeks after infection, and the number of CFU was counted in the spleen, liver, and lungs. Figure 5 shows representative data of one of two experiments performed. Treatment with CLA alone decreased bacterial growth in the lungs (1.5-log reduction, Fig. 5B), spleen (3.5-log reduction, Fig. 5C), and liver (4-log reduction, Fig. 5D) in this therapeutic model. ISS-ODN alone did not inhibit the growth of *M. avium*. However, when ISS-ODN was combined with CLA, there was a further reduction of bacterial counts, particularly in the lungs (3-log reduction, *P* < 0.01, Fig. 5B to D) and in the spleen (2-log reduction, *P* < 0.01, Fig. 5B).

Despite the fact that treatment with ISS-ODN postinfection did not affect the course of the infection in vivo, these findings suggest that ISS-ODN can enhance the therapeutic efficacy of CLA in the setting of established *M. avium* infection. Tissue sections from spleen fixed and stained with hematoxylin-eosin showed that the white pulp from *M. avium*-infected mice treated with PBS was replaced with granulomas. The spleen sections from infected mice treated with CLA showed fewer granulomas with smaller sizes compared to the infected mice treated with PBS. The sections from infected mice treated with ISS-ODN alone or CLA plus ISS-ODN showed even smaller granulomas in the white pulp and increased mononuclear cells in the red pulp compared to those in the infected mice treated with PBS or CLA alone, respectively.

**ISS-ODN inhibits *M. avium* growth in human macrophages in vitro.** To study the relevance of the antimycobacterial effects of ISS-ODN in humans, hMDMs were treated with ISS-ODN or M-ODN (3, 10, and 30 μg/ml) for 3 days and then infected with *M. avium*. There was maximal inhibition of *M. avium* growth at 3 μg of ISS-ODN per ml (Fig. 6A) with no further increase in inhibition at the higher concentrations (data not shown). At 7 days postinfection, treatment with ISS-ODN inhibited intracellular growth of *M. avium* by 91% (Fig. 6A, *P* < 0.001). No changes in cell viability were observed in the various groups. To study the therapeutic effects of ISS-ODN on established *M. avium* infection, infected hMDMs were treated with ISS-ODN (10 μg/ml) for 7 days. Treatment with ISS-ODN...
significantly decreased the intracellular growth of *M. avium* in hMDMs by 53% (*P < 0.05*) (Fig. 6B). When infected cells were treated with ISS-ODN together with CLA (0.1 μg/ml), *M. avium* growth was further inhibited up to 99% (*P < 0.01*), compared to medium alone (Fig. 6B). These findings indicate that ISS-ODN can provide a significant antimycobacterial effect in human macrophages as well as in the mouse model.

**DISCUSSION**

This study demonstrates that ISS-ODN augments host resistance against *M. avium* infection and that the induction of IDO plays an important role in this effect. Furthermore, ISS-ODN synergizes with the chemotherapeutic drug CLA to further promote mycobacterial clearance. These data support recent reports showing that administration of ISS-ODN provides protection against the intracellular pathogens *Listeria monocytogenes* (27), *Leishmania major* (51), and *Francisella tularensis* (15). Studies with *L. monocytogenes* showed that injection of mice with *Escherichia coli* DNA or ISS-ODN resulted in a much lower bacterial burden in the spleen and liver (27). Similarly, ISS-ODN conferred a protective immunity against primary infection and resistance to secondary infection with *L. major* (51). This antimicrobial activity was attributed mainly to ISS-ODN-induced release of cytokines such as IL-12 and to the subsequent induction of a protective Th1 and/or CTL response. Indeed, administration of exogenous IL-12 or IFN-γ, which are induced by ISS-ODN, increases protection against *L. major* (51).

Our study suggests that ISS-ODN-induced resistance to *M. avium* infection does not act via augmentation of the adaptive T-cell response. First, the in vitro studies showed that treatment with ISS-ODN enhanced the ability of macrophages to resist *M. avium* growth despite the absence of T cells (Fig. 1). Second, ISS-ODN-induced resistance to *M. avium* in vivo decayed by 6 weeks, at which point ISS-ODN-treated mice had the same mycobacterial burden as control, PBS-treated mice (Fig. 2). The induction of a protective antimycobacterial T-cell response would be expected to provide a long-lasting antimycobacterial effect, rather than the transient protective effect response would be expected to provide a long-lasting antimycobacterial effect.

Further study is necessary to determine whether other factors or mechanisms are involved in the antimycobacterial effect of ISS-ODN in vivo.

ISS-ODN was initially identified in mycobacterial genomes (50), and it is well known that mycobacterial DNA is immunostimulatory. This raises a question: why is it that the *M. avium* genomic DNA contained within infected cells such as macrophages does not facilitate the clearance or inhibit the growth of this intracellular pathogen? A potential explanation for this paradox may lie in the recent observation that agents such as chloroquine (31), which inhibits the acidification of lysosomes, neutralize the immunostimulatory effects of ISS-ODN. Interestingly, mycobacteria also inhibit the generation of low pH in the lysosomes (49). Therefore, neutralization of the acidic environment of the lysosome may protect *M. avium* both directly, by avoiding digestion, and indirectly, by blocking the detection of its own immunostimulatory genomic DNA by the host cell.

The antimycobacterial effect of ISS-ODN in vivo on established *M. avium* infection is less than its effect when used prior to infection, while ISS-ODN significantly inhibits *M. avium* growth in vitro (Fig. 1B). In vivo, *M. avium* delivered i.v. can infect different macrophage populations, such as splenic macrophages, alveolar macrophages, and peritoneal macrophages. Peripheral macrophage populations have been shown to ex-
hbit distinct functional phenotypes, including cytokine production, response to immunomodulatory stimuli, and clearance of pathogens (reviewed in reference 45). Gandh Adriamar and Pratt reported that alveolar macrophages and peritoneal macrophages have the distinct ability to ingest and control the multiplication of Mycobacterium cells (19). Alveolar macrophages are known to release more nitrate than peritoneal macrophages when exposed to LPS and IFN-γ in C3H/HeJ mice (52). Indeed, in our preliminary study, alveolar macrophages, splenic macrophages, and BMDMs show unique individual patterns of cytokine secretion induced by ISS-ODN (data not shown). It is likely that various macrophage populations behave differently in response to ISS-ODN and M. avium infection.

Although treatment of macrophages with ISS-ODN inhibited M. avium growth in vitro, in vivo administration of ISS-ODN alone to mice with an established M. avium infection had no protective effect (Fig. 5B). However, when ISS-ODN was used together with CLA, there was a synergistic anti-M. avium therapeutic effect in mouse and human macrophages in vitro. This synergism might be due to more effective protein synthesis inhibition. CLA inhibits protein synthesis by binding to the 50S ribosome, while IDO induced by ISS-ODN interferes with protein synthesis by depletion of tryptophan. In vivo experiments, ISS-ODN plus CLA showed a significant though modest synergistic therapeutic effect. Additional work is required with different doses and timing of ISS-ODN administration in order to optimize combined therapy as an alternate regimen in the treatment of established M. avium infection.

In summary, this study demonstrates that administration of ISS-ODN enhances resistance against M. avium infection through the induction of IDO. ISS-ODN itself provides limited protection against M. avium. However, this effect can be amplified upon codelivery with an antimycobacterial drug. The combined administration of ISS-ODN with other antibiotics or other antimicrobial agents provides a novel therapeutic strategy for microbial infections and warrants further investigation.

ACKNOWLEDGMENTS

Funds from the National Institutes of Health (grants AI40682 and AI47078 to E.R., AI35258 and HL57911 to R.S.K., and AR44850 for D.A.C) and from Dynavax Technologies Corporation and Sequella AI47078 to E.R., AI35258 and HL57911 to R.S.K., and AR44850 for D.A.C. We thank Sunil J. Sahdeo for excellent technical assistance. We also thank Lucinda Beck for helpful editorial assistance.

REFERENCES


